drugset
drugset / Trial / NCT01351766

Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation

NCT01351766 ↗

Phase 3 Completed 39 enrolled University of Maryland, College Park National Institute on Drug Abuse (NIDA) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to develop a specialized behavioral activation treatment for smoking in youths ages 18-21 with elevated depressive symptoms. In the first phase we utilize focus groups and pilot testing with 15 youths to develop the behavioral activation smoking treatment for youth. In Phase II, we will conduct an open-label trial of the new treatment that will include 8 weeks of transdermal nicotine patch, which will begin at the time of quitting smoking. Participants will be followed over 26 weeks post-quit date. A subset of participants will also undergo an fMRI session to examine reward sensitivity.

Timeline

Start
2010-04
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Transdermal Nicotine Patch Unknown 7 mg Other
Subject Transdermal Nicotine Patch Unknown 14 mg Other
Subject Transdermal Nicotine Patch Unknown 21 mg Other

Indications

No indication recorded.